Payment overview · 2025
General Payments
$684.11
25 reported records · 12 companies
Healthcare provider profile · identity verified
Gerald Gordon, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · AIKEN, SC · NPI 1396738753
Verified facts
What the public records show
CMS Open Payments records show Gerald Gordon, M.D. received $684.11 in general payments during 2025 across 25 reported records.
AstraZeneca Pharmaceuticals LP accounted for 29.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Korlym.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Farxiga by this doctor in 2024.
Corcept Therapeutics reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Korlym as an associated drug or biological on 56316 records involving 19205 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Korlym by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $198.32 | 29.0% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $157.47 | 23.0% | 7 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $67.98 | 9.9% | 3 | 2025 |
| Shionogi Inc | Unresolved — no canonical attribution shown | $65.10 | 9.5% | 3 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $39.28 | 5.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.02 | 4.1% | 2 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $26.82 | 3.9% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $23.92 | 3.5% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $21.19 | 3.1% | 1 | 2025 |
| Ferring Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.90 | 3.1% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $19.64 | 2.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.47 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $684.11 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $157.47 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $99.95 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $98.37 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $67.98 | 3 | 2025 |
Source payment records
|
|||||
| Fetroja Normalized: fetroja |
Drug | Shionogi Inc | $65.10 | 3 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $46.14 | 2 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $39.28 | 2 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $39.28 | 2 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $39.28 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $28.02 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $28.02 | 2 | 2025 |
Source payment records
|
|||||
| Xembify Normalized: xembify |
Biological | Grifols USA, LLC | $26.82 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $23.92 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $21.19 | 1 | 2025 |
Source payment records
|
|||||
| REBYOTA Normalized: rebyota |
Biological | Ferring Pharmaceuticals Inc. | $20.90 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $19.64 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Korlym korlym |
2025 | Korlym | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
47 | 14 |
| Corcept Therapeutics Exact reporting entity; no affiliate inference |
2025 | Korlym open payments reported associated product |
CMS Open Payments — General Payments 56316 supporting records · 19205 recipient NPIs · example record 1214133822 |
Korlym · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
109 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 300 | 76 |
| Atorvastatin Calcium | Atorvastatin Calcium | 263 | 77 |
| Losartan Potassium | Losartan Potassium | 241 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 226 | 66 |
| Alprazolam | Alprazolam | 186 | 39 |
| Amlodipine Besylate | Amlodipine Besylate | 162 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 139 | 44 |
| Ezetimibe | Ezetimibe | 138 | 40 |
| Omeprazole | Omeprazole | 125 | 35 |
| Metformin Hcl | Metformin Hcl | 115 | 34 |
| Eliquis | Apixaban | 109 | 23 |
| Ozempic | Semaglutide | 108 | 19 |
| Nifedipine Er | Nifedipine | 106 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 104 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 103 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 100 | 31 |
| Gabapentin | Gabapentin | 98 | 22 |
| Montelukast Sodium | Montelukast Sodium | 97 | 37 |
| Metformin Hcl Er | Metformin Hcl | 83 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 25 |
| Furosemide | Furosemide | 80 | 24 |
| Simvastatin | Simvastatin | 80 | 22 |
| Carvedilol | Carvedilol | 69 | 18 |
| Lisinopril | Lisinopril | 69 | 21 |
| Januvia | Sitagliptin Phosphate | 68 | 14 |
| Clonazepam | Clonazepam | 67 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | 18 |
| Jardiance | Empagliflozin | 62 | 17 |
| Allopurinol | Allopurinol | 61 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 59 | 18 |
| Torsemide | Torsemide | 55 | 18 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 54 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 50 | 12 |
| Trulicity | Dulaglutide | 50 | suppressed |
| Myrbetriq | Mirabegron | 49 | suppressed |
| Famotidine | Famotidine | 48 | 17 |
| Farxiga | Dapagliflozin Propanediol | 47 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 47 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 46 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 22 |
| Potassium Chloride | Potassium Chloride | 44 | suppressed |
| Atenolol | Atenolol | 42 | 11 |
| Memantine Hcl | Memantine Hcl | 42 | suppressed |
| Celecoxib | Celecoxib | 40 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 40 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 38 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | suppressed |
| Mirtazapine | Mirtazapine | 37 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 36 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 36 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 14 |
| Irbesartan | Irbesartan | 35 | suppressed |
| Prednisone | Prednisone | 35 | suppressed |
| Lorazepam | Lorazepam | 33 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 17 |
| Colchicine | Colchicine | 32 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 32 | 12 |
| Linzess | Linaclotide | 31 | suppressed |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | 11 |
| Trazodone Hcl | Trazodone Hcl | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Cilostazol | Cilostazol | 28 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Creon | Lipase/Protease/Amylase | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 20 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 19 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 19 | suppressed |
| Edarbi | Azilsartan Medoxomil | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 14 |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Lubiprostone | Lubiprostone | 17 | suppressed |
| Rexulti | Brexpiprazole | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Kerendia | Finerenone | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Dicloxacillin Sodium | Dicloxacillin Sodium | 14 | suppressed |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Oxacillin Sodium | Oxacillin Sodium | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Cefazolin Sodium | Cefazolin Sodium | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Ertapenem | Ertapenem Sodium | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Tivicay | Dolutegravir Sodium | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Korlym | Mifepristone | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $684.11 · 25 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, Arikayce, BREZTRI, Brinsupri, COMIRNATY, FLOWTRIEVER, Fetroja, INJECTAFER, Korlym, LEQVIO, PREVNAR 20, REBYOTA, VERQUVO, Xembify, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Korlym play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error